Master Gout Management and Go for Six!

Hello Gout Education,

The Gout Education Society is committed to raising awareness of gout—the most common form of inflammatory arthritis. The Society arms healthcare professionals, like you, with resources to share with patients and staff—and provides you with access to the most up-to-date research and information about gout and treatment options through GoutEducation.org.

Gout is notorious for its acute flares, which can be debilitating for patients. By maintaining uric acid levels within the recommended range of below 6.0 mg/dL, the frequency and severity of flares can be significantly reduced, improving quality of life and decreasing the risk of long-term complications such as joint damage, tophi formation, and even kidney stones.

The Gout Education Society's Go For Six campaign addresses gaps in awareness and promotes the need for consistent uric acid testing and treatment. This initiative aligns with ACR and EULAR guidelines, advocating for uric acid testing every six months and continuous treatment until levels reach the target threshold of below 6.0 mg/dL.

Despite the campaign's efforts, awareness levels remain low. Eight in 10 Americans are unaware of the target uric acid level for gout and half of those diagnosed with gout don't understand the importance of keeping tabs on their uric acid levels regularly. This is why, beyond rheumatology circles, this message needs to reach the front lines of healthcare and primary care physicians who are the first line of defense in diagnosing and managing gout.

Help your patients by sharing our variety of educational resources and help yourself by learning more about our Go for Six campaign from our 2019 roundtable consensus paper on the topic here!

Have any questions or need resources? Email us: info@gouteducation.org.

New Resource:

A Multidisciplinary Approach To Managing Gout: A Roundtable Discussion

New Blog:

Gout and Alzheimer’s Disease: What Should I Know?

"If you take treatment for gout to reduce uric your acid levels to under 6 mg/dL, you will have a major benefit to reduce your risk for dementia and potentially live longer."

Help Patients Find Gout Treatment Faster!

Are you a part of our Gout Specialists Network (GSN)?

Joining is easy:

1. To sign up, visit GoutSpecialistsNetwork.org.
2. After you register free of charge, update your profile page with information about yourself and your practice.
3. Enjoy ongoing access to the latest gout information, research and continuing education.

As a member, you can choose to make your practice and professional information available to patients through a medical professional locator—helping those with gout find qualified medical professionals in their area.

Clinical Trial Seeks People with Hyperuricemia

Tigulixostat, a xanthine oxidase inhibitor, will be studied in a clinical trial. LG Chem is looking for participants from several different regions.

The Phase 3 clinical trial intends to test the drug’s effectiveness for 12 months in people with hyperuricemia versus those who are given a placebo.

Find out who is eligible and how patients can sign up on clinicaltrials.gov

Clinical Trial Seeks People with an Acute Gout Attack

Olatec Therapeutics is seeking participants for its Phase 2/3 clinical trial in patients with an acute gout flare. The objective of the clinical trial is to test an oral anti-inflammatory, called dapansutrile, which is an investigational drug not yet approved by FDA. The trial will assess the effectiveness of dapansutrile in treating inflammatory pain over 8 days in people with gout who are experiencing an acute gout attack versus those who are given a placebo. Rescue treatment is offered if pain remains intolerable while on study. 

The trial is seeking participants located throughout the United States and Europe. 

To find out who is eligible and how patients can sign up please visit clinicaltrials.gov and/or contact gout@olatec.com 

Clinical Trial Seeks Patients with Gout for Oral Drug

Atom Biosciences is seeking participants for its Phase 2b/3 clinical trial in patients with gout. In this study named GUARD, doctors are investigating a oral study drug called ABP-671 to find out how well it works compared to an approved gout medication and placebo. Gout is one of the most common types of inflammatory arthritis, characterized by sudden severe attacks of pain, swelling, redness and tenderness in the joints. The study drug is a substance that is being tested in clinical studies and is not yet approved by regulatory agencies. Placebo is a substance that looks like the study drug but has no active drug in it. The multicenter, randomized, double-blind trial will enroll patients worldwide, including in the U.S. To find out who is eligible and how patients can sign up please visit:

StudyKik Website

Stay up to date on the most recent gout news